| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2022 | Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety | YU-YUN SHAO ; Feng Y.-H.; Yen C.-J.; Yang T.-S.; Shen Y.-C.; Chao Y.; Chen J.-S.; Su C.-Y.; Chen W.-J.; Hsiang H.-L.; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 1 | 1 | |
| 2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 39 | 40 | |
| 2011 | The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis | Hwang J.-S.; Chin L.-S.; Chen J.-F.; Yang T.-S.; Chen P.-Q.; KEH-SUNG TSAI ; Leung P.C. | Journal of Bone and Mineral Metabolism | 25 | 24 | |
| 2009 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | ANN-LII CHENG ; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. | The Lancet Oncology | 4451 | 4274 | |
| 2012 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial | ANN-LII CHENG ; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K. | European Journal of Cancer | 198 | 203 | |
| 2010 | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Yang T.-S.; CHIUN HSU ; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN ; ZHONG-ZHE LIN ; Chao T.-Y.; ANN-LII CHENG | British Journal of Cancer | 112 | 111 | |
| 2017 | Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study | ANN-LII CHENG ; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; KUN-HUEI YEH ; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. | Clinical Colorectal Cancer | 16 | 15 | |
| 2017 | Generation of GGTA1 Mutant Pigs by Direct Pronuclear Microinjection of CRISPR/Cas9 Plasmid Vectors | Chuang C.-K.; Chen C.-H.; Huang C.-L.; Su Y.-H.; Peng S.-H.; Lin T.-Y.; HAO-CHIH TAI ; Yang T.-S.; Tu C.-F. | Animal Biotechnology | 31 | 28 | |
| 2006 | The hDAF Exogene Protects Swine Endothelial and Peripheral Blood Mononuclear Cells From Xenoreactive Antibody Mediated Cytotoxicity in hDAF Transgenic Pigs | JANG-MING LEE ; Tu C.-F.; HAO-CHIH TAI ; NAI-KUAN CHOU ; Yang T.-S.; Weng C.-N.; Lee Y.-C.; Lee C.-J.; PO-HUANG LEE | Transplantation Proceedings | 3 | 4 | |
| 2018 | Healthcare-associated infections in intensive care units in Taiwan, South Korea, and Japan: Recent trends based on national surveillance reports | Chiang C.-H.; SUNG-CHING PAN ; Yang T.-S.; Matsuda K.; Kim H.B.; Choi Y.H.; Hori S.; JANN-TAY WANG ; WANG-HUEI SHENG ; YEE-CHUN CHEN ; Chang F.-Y.; SHAN-CHWEN CHANG | Antimicrobial Resistance and Infection Control | 25 | 22 | |
| 2008 | Human Leukocyte Antigen-DR Matching Improved Skin Graft Survival From Transgenic Pigs to Accommodate SCID Mice Reconstituted With Human Peripheral Blood Mononuclear Cells | Tu C.-F.; HAO-CHIH TAI ; Chen C.-M.; Huang T.-T.; JANG-MING LEE ; Yang T.-S.; Chen C.-H.; Tseng Y.-L.; NAI-KUAN CHOU ; PO-HUANG LEE | Transplantation Proceedings | 2 | 1 | |
| 2010 | The in vitro protection of human decay accelerating factor and hDAF/heme oxygenase-1 transgenes in porcine aortic endothelial cells against sera of formosan macaques | Tu C.-F.; HAO-CHIH TAI ; Wu C.-P.; Ho L.-L.; Lin Y.-J.; Hwang C.-S.; Yang T.-S.; JANG-MING LEE ; Tseng Y.-L.; Huang C.-C.; Weng C.-N.; PO-HUANG LEE | Transplantation Proceedings | 5 | 5 | |
| 2008 | Long-Term Survival of HLA-DR15+ Pig Skin in SCID Mice After Reconstitution With Human Peripheral Blood Mononuclear Cells and Under Short-Term Immunosuppression | HAO-CHIH TAI ; Tu C.-F.; JANG-MING LEE ; Ho L.-L.; Tseng Y.-L.; NAI-KUAN CHOU ; Yang T.-S.; Weng C.-N.; PO-HUANG LEE ; KING-JEN CHANG ; Tang Y.-B. | Transplantation Proceedings | 1 | 1 | |
| 2010 | A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients | Yang T.-S.; Lu S.-N.; Chao Y.; Sheen I.-S.; Lin C.-C.; Wang T.-E.; Chen S.-C.; Wang J.-H.; Liao L.-Y.; Thomson J.A.; Wang-Peng J.; PEI-JER CHEN ; Chen L.-T. | British Journal of Cancer | 126 | 120 | |
| 2016 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma | ANN-LII CHENG ; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. | Hepatology | 61 | 62 | |
| 2021 | Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan | KUN-HUEI YEH ; Yang T.-S.; Hsu T.-C.; Tzu-Liang Chen W.; Chen H.-H.; Teng H.-W.; Lin B.-W.; Kuan F.-C.; Chiang F.-F.; Duann C.-W.; Li Y.-S.; Lin M.-T.; Fiala-Buskies S.; Ducreux M.; Wang J.-Y. | Journal of the Formosan Medical Association | 3 | 2 | |
| 2020 | Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study | CHIA-CHI LIN ; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU | Oncologist | 3 | 2 | |
| 2020 | Scaffold derived from GGTA1 and CMAH double knockout pigs elicits only slight inflammation in a gene-edited pig model | Yen C.-H.; HAO-CHIH TAI ; Peng S.-H.; Yang T.-S.; Tu C.-F. | Materialia | 3 | 3 | |
| 2012 | Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study | CHIUN HSU ; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; CHIH-WEI YU ; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; ANN-LII CHENG | Journal of Hepatology | 73 | 70 | |
| 2011 | Who Can Pass the ISCD Professional Certification Course? The 8-Yr Experience in Taiwan | Wu M.-C.; Wu C.-H.; Soong Y.-K.; Lin R.-M.; Yang T.-S.; Chen J.-F.; KEH-SUNG TSAI | Journal of Clinical Densitometry | 0 | 0 | |
